<DOC>
	<DOCNO>NCT01938014</DOCNO>
	<brief_summary>Hypothesis : Children diagnose lysosomal disease exhibit developmental , adaptive , behavioral strength difficulty depend upon 1 ) biomedical risk factor ( i.e . specific genetic disorder responsible illness ) ; 2 ) available modify intervention , whether medical behavioral ; 3 ) social risk child 's family , neighborhood community . A valid reliable telephone-based surveillance system successfully collect data require elucidate developmental , adaptive behavioral strength difficulty .</brief_summary>
	<brief_title>Lysosomal Storage Disease : Health , Development , Functional Outcome Surveillance Preschool Children</brief_title>
	<detailed_description>Children lysosomal disease experience decline health status central nervous system integrity result motor , communication , self-care , learn behavioral challenge . Medical intervention enzyme replacement therapy ( ERT ) hematopoietic stem cell transplantation improve health function child lysosomal disease . To date , however , establish system evaluate health status , developmental status , behavioral outcome functional outcome preschool-aged child across time differ setting . The primary objective study develop valid reliable telephone-based data-gathering system obtain health status data , developmental status data , behavioral outcome data , functional outcome data reflect skill daily live include feeding , move , communicate respond others . The secondary objective study assess validity several early-childhood standardized assessment tool compare standard neuropsychological assessment battery specify Lysosomal Disease Network 's 'Neurobehavioral Core . ' The third objective study describe impact lysosomal disease upon family lysosomal disease-affected child .</detailed_description>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Lysosomal Storage Diseases</mesh_term>
	<mesh_term>Leukodystrophy , Globoid Cell</mesh_term>
	<mesh_term>Mucopolysaccharidosis I</mesh_term>
	<mesh_term>Mucopolysaccharidosis II</mesh_term>
	<mesh_term>Mucopolysaccharidosis VI</mesh_term>
	<mesh_term>Mucopolysaccharidosis III</mesh_term>
	<criteria>Children age 1 84 month diagnose MPS type I , II , III VI . Children age 1 84 month diagnose lysosomal disease . Children age birth 18 year diagnose Krabbe disease , positive screening Krabbe disease . Children lysosomal disease exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>MPS I</keyword>
	<keyword>MPS II</keyword>
	<keyword>MPS III</keyword>
	<keyword>MPS VI</keyword>
	<keyword>Krabbe disease</keyword>
	<keyword>globoid cell leukodystrophy</keyword>
	<keyword>galactosylceramide lipidosis</keyword>
	<keyword>mucopolysaccharidoses</keyword>
	<keyword>mucopolysaccharidosis</keyword>
	<keyword>Rare Diseases Clinical Research Network</keyword>
	<keyword>Lysosomal Disease Network</keyword>
	<keyword>enzyme replacement therapy</keyword>
	<keyword>hematopoietic stem cell transplant</keyword>
	<keyword>telephone-based surveillance</keyword>
	<keyword>Hurler syndrome</keyword>
	<keyword>Hunter syndrome</keyword>
	<keyword>Scheie syndrome</keyword>
	<keyword>Hurler-Scheie syndrome</keyword>
	<keyword>Sanfilippo syndrome</keyword>
	<keyword>Maroteaux-Lamy syndrome</keyword>
</DOC>